This is a multicentre, non-interventional, single arm study that aims to describe the treatment patterns in France: patients' characteristics, disease characteristics, prior treatments for Severe chronic rhinosinusitis with nasal polyposis and treatment prescription modalities. As well as to assess the clinical outcome after initiation of dupilumab (Dupixent®) and safety of the product during the two years of treatment
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Patient characteristics: Age
Timeframe: At baseline (Day 1)
Patient characteristics: Sex
Timeframe: At baseline (Day 1)
Patient characteristics: Weight
Timeframe: At baseline (Day 1)
Patient characteristics: Height
Timeframe: At baseline (Day 1)
Patient characteristics: Type 2 comorbidities
Timeframe: At baseline (Day 1)
Patient characteristics: Medical history
Timeframe: At baseline (Day 1)
Patient characteristics: Lifestyle habits
Timeframe: At baseline (Day 1)
Disease characteristics: CRSwNP duration
Timeframe: At baseline (Day 1)
Disease characteristics: Age at diagnosis of CRSwNP
Timeframe: At baseline (Day 1)
Disease characteristics: Blood Eosinophils
Timeframe: At baseline (Day 1)
Disease characteristics: Total serum IgE
Timeframe: At baseline (Day 1)
Disease characteristics: Anatomopathology
Timeframe: At baseline (Day 1)
Disease characteristics: Nasal polyps score (NPS) at baseline
Timeframe: At baseline (Day 1)
Disease characteristics: Nasal congestion score (NCS) at baseline
Timeframe: At baseline (Day 1)
Disease characteristics: Rhinorrhea score (anterior/posterior) at baseline
Timeframe: At baseline (Day 1)
Disease characteristics: VAS for CRSwNP symptoms at baseline
Timeframe: At baseline (Day 1)
Disease characteristics: smell test score Visual Analog Scale (VAS) at baseline
Timeframe: At baseline (Day 1)
Concomitant and prior medications for CRSwNP or other disease: Number of patients with at least one prior or concomitant SCS
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease:Type of prior Systemic Corticosteroids (SCS) per patient
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease: Cumulative dose of SCS
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease: Total number of SCS bursts per patient
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease: Recovery of sense of smell after SCS
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease:Time since the most recent SCS burst before initiation of Dupixent®
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease: Number of prior or respiratory concomitant biotherapies per patient
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other diseases: Indication
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other diseases: Reason for stop
Timeframe: From baseline up to 24 months.
Dupilumab (Dupixent®) modalities: Dosage
Timeframe: From baseline up to 24 months.
Dupilumab (Dupixent®) modalities: Injection modalities
Timeframe: From baseline up to 24 months.
Dupilumab (Dupixent®) modalities: Treatment duration
Timeframe: From baseline up to 24 months.
Dupilumab (Dupixent®) modalities: Compliance with treatment
Timeframe: From baseline up to 24 months.